[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nuvance Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100393729","the-role-of-microrna-in-the-diagnosis-prognosis-and-response-to-treatment-in-pancreatic-cancer-100393729",false,"NCT04406831","The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer","Inclusion Criteria:\n\n* Have biopsy proven adenocarcinoma of the pancreas\n* Have initially inoperable disease, classified as either locally advanced or metastatic disease\n\n  * Recurrent disease after a Whipple procedure is allowed\n  * Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection\n* Have radiographically measurable disease\n* Have an ECOG performance status of 2 or less\n* Be willing to contribute the required information and specimens\n* Provide written signed consent to participate\n\nExclusion Criteria:\n\n* Having received prior anti-cancer treatments for metastatic pancreatic cancer\n* Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable\u002Fcontrolled prostate cancer\n* Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \\>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \\> 5 years is allowable",true,"ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood\u002Fserum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.",[24,25,26,27],"Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms",[29,30,31],"Pancreas","Cancer","Biomarker","RECRUITING","2026-04-06",{"date":35,"type":36},"2026-04-13","ACTUAL",{"date":38,"type":36},"2015-04",{"date":40,"type":20},"2030-04",{"name":42,"class":43},"Nuvance Health","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100357699","a-pancreatic-cancer-screening-study-in-individuals-with-new-onset-or-deteriorating-diabetes-mellitus-100357699","NCT03937453","A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus","A PAncreatic Cancer Screening Study in Individuals With New-Onset or DeteriOrating Diabetes MEllitus (PANDOME Study)","PANDOME","Inclusion Criteria:\n\n* Age of at least 50 years.\n* DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR\n* DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR\n* Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR\n* DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%. OR\n* Deteriorating Diabetes: DM with \\>2% spike in HbA1c within past 6 months confirmed with repeat testing and NOT associated with weight gain and diabetes medication non-compliance\n* ECOG Performance Status of 0-1.\n* No known contraindications to MRI examination or gadolinium contrast.\n* Willing to undergo MRI and screening for metal implants or metal injury.\n* Ability to provide informed consent.\n* Willing to return to study site for all study assessments.\n\nExclusion Criteria:\n\n* Prior history of pancreatic cancer.\n* Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\n* Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\n* Hereditary pancreatitis.\n* Use of high dose glucocorticoid steroids (at least 20 mg daily of prednisone) within 3 months of diabetes diagnosis or elevation of HbA1c. Lower doses of steroid use as a cause of glucocorticoid-induced diabetes will be made on a case-by-case basis.\n* Contraindication to MRI examination or gadolinium contrast.\n* Pregnant or nursing women.\n* Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.","50 Years",{"count":55,"type":20},800,"The main goal of this study is to explore the relationship between new-onset diabetes mellitus\u002Fdeteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI\u002FMRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.",[58,27,59],"Pancreatic Cancer","Diabetes Mellitus",[29,30,59,61,62,63],"MRI","Early Detection","Screening",{"date":35,"type":36},{"date":66,"type":36},"2018-01-19",{"date":68,"type":20},"2028-01-19",{"name":42,"class":43},2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100304968","a-pancreatic-cancer-screening-study-in-hereditary-high-risk-individuals-100304968","NCT03250078","A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals","Registration-Inclusion Criteria for FAMILIAL PANCREATIC CANCER (FPC) and those with a BRCA1, BRCA2, LYNCH SYNDROME, ATM, PALB2, CDKN2A, or related gene mutation (one of the following is required for questions 1-3)\n\n1. For FPC: The individual has at least 2 first-degree relatives (FDR) with PC.\n2. For FPC: The individual has at least 3 first-, second-, or third-degree relatives with PC with at least 1 PC in a FDR.\n3. The individual is a known mutation carrier of BRCA1, BRCA2, MLH1, MSH2, MSH6, or PMS2, ATM, PALB2, CDKN2A, or similar high-risk gene mutation and has at least 1 first- or second-degree relative with PC.\n4. The individual is at least 50 years old or 10 years younger than the youngest relative with PC.\n5. ECOG Performance Status of 0-1.\n6. No known contraindications to MRI examination or gadolinium contrast.\n7. Willing to undergo MRI and screening for metal implants or metal injury.\n8. Estimated GFR \\>29 mL\u002Fmin\n9. Ability to provide informed consent.\n10. Willing to return to study site for all study assessments.\n\nRegistration-Exclusion Criteria:\n\n1. Prior history of pancreatic cancer.\n2. Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.\n3. Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).\n4. Hereditary pancreatitis.\n5. eGFR \\\u003C 30 mL\u002Fmin\n6. Contraindication to MRI examination or gadolinium contrast.\n7. Pregnant or nursing women.\n8. Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.","90 Years",{"count":19,"type":20},"The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI\u002FMRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for Pancreatic Cancer.",[27],[29,30,61,82,62,83,84,85,86,87],"BRCA","Genetics","ATM","PALB2","Lynch","CDKN2A",{"date":35,"type":36},{"date":90,"type":4},"2016-11",{"date":92,"type":20},"2030-11",{"name":42,"class":43},""]